<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ASH</title>
	<atom:link href="http://www.stockbloghub.com/tag/ash/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(DOW) Three More Industries Thriving From Record-Low Natural Gas Prices</title>
		<link>http://www.stockbloghub.com/2012/01/31/dow-three-more-industries-thriving-from-record-low-natural-gas-prices/90748</link>
		<comments>http://www.stockbloghub.com/2012/01/31/dow-three-more-industries-thriving-from-record-low-natural-gas-prices/90748#comments</comments>
		<pubDate>Tue, 31 Jan 2012 16:50:39 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[Eastman Chemical Company]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[EMN]]></category>
		<category><![CDATA[Enterprise Products Partners Lp]]></category>
		<category><![CDATA[EPD]]></category>
		<category><![CDATA[HMC]]></category>
		<category><![CDATA[Honda Motor Company Limited]]></category>
		<category><![CDATA[MEOH]]></category>
		<category><![CDATA[Methanex Corporation]]></category>
		<category><![CDATA[RDSA]]></category>
		<category><![CDATA[Royal Dutch Shell Plc]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90748</guid>
		<description><![CDATA[by Mike Kapsch, Investment U Research Tuesday, January 24, 2012 Since hitting a high of $15.37 in December 2005, the price of natural gas has plunged to its lowest level in over a decade to $2.30. That’s an 85% drop. As Reuters recently reported, “The unrelenting surge in shale gas production and one of the warmest winters on record are driving the natural gas market toward uncharted territory. Soon companies may have to pay to get rid of their gas.” So far, this has been tough news for natural gas drillers and electric utilities. Many drillers are ramping up their oil production, trying to make up for lost income. Chesapeake Energy even cut its gas drilling production in half, which led to a bit of a rally over the past ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/31/dow-three-more-industries-thriving-from-record-low-natural-gas-prices/90748/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278</link>
		<comments>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278#comments</comments>
		<pubDate>Fri, 09 Dec 2011 17:40:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88278</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also adjusting for the change in fair value of warrants). Lower-than-expected revenues led to the wider loss in the quarter. Revenues at Micromet were down almost 33% from the prior-year period to $4.5 million in the third quarter of 2011 due to lower collaboration revenue. Moreover, revenues in the year-ago quarter were boosted by the presence of a milestone payment from AstraZeneca (AZN). Revenues were also much below the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CE) Celanese Acquires Ashland Assets</title>
		<link>http://www.stockbloghub.com/2011/11/12/ce-celanese-acquires-ashland-assets/86950</link>
		<comments>http://www.stockbloghub.com/2011/11/12/ce-celanese-acquires-ashland-assets/86950#comments</comments>
		<pubDate>Sat, 12 Nov 2011 21:48:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86950</guid>
		<description><![CDATA[Celanese Corporation (CE) entered into an agreement to acquire polyvinyl acetate assets from Ashland Inc. (ASH), including two product lines, Vinac and Flexbond. The transaction is expected to close within 60 days, subject to satisfaction of closing conditions. Terms were not disclosed. The acquisition will further the growth of the Emulsion Polymers business and will expand Celanese’ product portfolio. The combined revenues of the two products were $45 million in 2010. This transaction is consistent with Celanese’s strategy to create shareholder value through strategic portfolio enhancements. Recently, Celanese reported adjusted earnings of $1.27 per share in the third quarter of 2011, beating the Zacks Consensus Estimate of $1.11. Diluted earnings per share in the quarter were $1.05, up 12.9% year over year. Quarterly revenues grew 20% year over year to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/12/ce-celanese-acquires-ashland-assets/86950/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFAM) Company News for June 21, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924</link>
		<comments>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924#comments</comments>
		<pubDate>Tue, 21 Jun 2011 15:28:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Home Health Care]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AFAM]]></category>
		<category><![CDATA[Agrium Inc.]]></category>
		<category><![CDATA[AGU]]></category>
		<category><![CDATA[Almost Family Inc.]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Carpenter Technology Corporation]]></category>
		<category><![CDATA[CRS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Harbin Electric Inc.]]></category>
		<category><![CDATA[HRBN]]></category>
		<category><![CDATA[PETM]]></category>
		<category><![CDATA[Petsmart Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SWKS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76924</guid>
		<description><![CDATA[•    Manufacturer and distributors of stainless steel and titanium products, Carpenter Technology (NYSE:CRS)  has concluded a merger agreement with Latrobe Specialty Metals as per which the former will acquire the latter in a deal worth around $558 million •    Shares of PNC Financial Services (NYSE:PNC) fell marginally, by 1.96% after the company announced it was acquiring the U.S. retail banking operations of the Royal Bank of Canada for $3.45 billion •    Chinese electric-motor manufacturer Harbin Electric (NASDAQ:HRBN) has entered into a definitive agreement as per which it will be acquired by a company owned by Chairman and Chief Executive Tianfu Yang for $744 million •    Share prices of Agrium Inc. (NYSE:AGU) jumped 4.05% to close at $82.98 after the company increased its outlook for second quarter earnings. Agrium said strong ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGYS) Company News for June 01, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/01/agys-company-news-for-june-01-2011-corporate-summary/75280</link>
		<comments>http://www.stockbloghub.com/2011/06/01/agys-company-news-for-june-01-2011-corporate-summary/75280#comments</comments>
		<pubDate>Wed, 01 Jun 2011 15:47:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Agilysys Inc.]]></category>
		<category><![CDATA[AGYS]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[Central Vermont Public Service Corporation]]></category>
		<category><![CDATA[CV]]></category>
		<category><![CDATA[GD]]></category>
		<category><![CDATA[General Dynamics Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[Radian Group Inc.]]></category>
		<category><![CDATA[RDN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75280</guid>
		<description><![CDATA[•    Ship builder General Dynamics Corp.’s (NYSE:GD) share prices rose 4.15% to $74.22 after the company after it announced that it would receive an additional $744 million from the Defense Department which has expanded a preexisting contract •    Analysts at Piper Jaffray (NYSE:PJC) raised the shares of Radian Group (NYSE:RDN) from &#8220;Neutral&#8221; rating to &#8220;Over Weight&#8221; rating •    Broadcom Corporation (NASDAQ:BRCM) was upgraded by BMO Capital with an &#8220;Outperform&#8221; rating and a target price of $50 •    Share prices of software vendor Agilysys, Inc.’s (NASDAQ:AGYS) jumped 42.47% to $6.81 after the company announced plans to sell the technology solutions unit for $64 million •    Motor oil maker Ashland Inc&#8217;s (NYSE:ASH) share price increased 11.95% after the company said it will buy International Specialty Products Inc. in a deal worth $3.2 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/01/agys-company-news-for-june-01-2011-corporate-summary/75280/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Drug Gains on Positive Data</title>
		<link>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-drug-gains-on-positive-data/22630</link>
		<comments>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-drug-gains-on-positive-data/22630#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:51:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22630</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) oncology product Treanda could see a significant rise in demand thanks to encouraging data presented at the recently conducted annual meeting of the American Society of Hematology (ASH). Clinical data supporting the use of Treanda as a new standard of care in the first-line treatment of non-Hodgkin&#8217;s lymphoma (NHL) was presented at ASH. Data from an investigator-led proof-of-concept study demonstrated that newly diagnosed NHL patients who were treated with a combination of Treanda and Roche/Genentech&#8216;s Rituxan experienced superior progression-free survival (55 months) compared to patients treated with the current standard of care, Rituxan plus a chemotherapy cocktail known as CHOP (35 months). The Rituxan-Treanda therapy was also found to be safer, less toxic and better tolerated. Treanda is currently approved for the treatment of patients suffering from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-drug-gains-on-positive-data/22630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet &amp; Bayer Take a BiTE</title>
		<link>http://www.stockbloghub.com/2009/12/02/miti-micromet-bayer-take-a-bite/21804</link>
		<comments>http://www.stockbloghub.com/2009/12/02/miti-micromet-bayer-take-a-bite/21804#comments</comments>
		<pubDate>Wed, 02 Dec 2009 22:20:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21804</guid>
		<description><![CDATA[Micromet (MITI), a biopharmaceutical company, is dependent on many of its collaborating partners for its product portfolio. In this respect, the company received good news with Bayer exercising its option to develop a new bispecific T-cell engager (BiTE) antibody for the treatment of solid tumors. Bayer has exercised its option under the terms of the collaboration and license agreement entered in January 2009. Following this move by Bayer, both companies will be developing the drug under a formal collaboration. Micromet will be primarily responsible for the preclinical development of the BiTE antibody through the completion of phase 1 clinical trials. Thereafter, responsibility of the drug lies with Bayer, which will assume full control regarding its further development and commercialization. As per the deal, Micromet will receive an option exercise fee ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/miti-micromet-bayer-take-a-bite/21804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks</title>
		<link>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305</link>
		<comments>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305#comments</comments>
		<pubDate>Wed, 11 Nov 2009 21:51:36 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ARIA]]></category>
		<category><![CDATA[Ariad Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PARD]]></category>
		<category><![CDATA[Poniard Pharmaceuticals Inc]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20305</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that. But you know what? There are a lot of ways to make money from biotech stocks, too. If you know what to look for, that is. Two obvious examples include: Picking the company behind the next breakthrough drug for cancer or Alzheimer’s. Digging out companies that are likely takeover targets (something my colleague Louis Basenese does expertly in his Takeover Trader service), or landing lucrative drug partnership deals, which send the stocks higher. But there’s another excellent way that shorter-term investors can grab gains and profit from biotech sector… Follow the Biotech Sector Conference Buzz Throughout the year, the biotech sector holds many key conferences where ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ASH) Ashland Inc. &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/06/24/ash-ashland-inc-value-zacks-rank-buy/8847</link>
		<comments>http://www.stockbloghub.com/2009/06/24/ash-ashland-inc-value-zacks-rank-buy/8847#comments</comments>
		<pubDate>Wed, 24 Jun 2009 20:57:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8847</guid>
		<description><![CDATA[Ashland Inc. (ASH), the chemical manufacturer, posted a big second quarter surprise as cost cutting helped the bottom line. The company has surprised on estimates 3 out of the last 4 quarters by an average of 15.32%. Company Description Ashland manufactures specialty chemical products for customers in 100 countries. The company has 5 segments: Ashland Aqualon Functional Ingredients, Ashland Hercules Water Technologies, Ashland Performance Materials, Ashland Consumer Markets (Valvoline) and Ashland Distribution. On June 22, the company announced it would sell its global marine services business, known as Drew Marine, to J.F. Lehman &#38; Company, a private equity firm, for $120 million before tax. The after-tax proceeds will be used to pay down debt. Drew Marine had revenue of approximately $140 million a year with employees in 47 countries. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/24/ash-ashland-inc-value-zacks-rank-buy/8847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

